Clinical Updates & Insights

Physicians from Memorial Sloan Kettering Cancer Center (MSK) have developed and validated clinical calculators to guide patients with colorectal cancer...

Memorial Sloan Kettering Cancer Center (MSK) researchers presented breakthrough findings for new treatment approaches in several cancer indications at the European Society for Medical Oncology (ESMO) Congress 2022, held September 9 to 13 in Paris. Highlights included clinically meaningful benefits for new treatment strategies in advanced bladder cancer, endometrial cancer, and renal cell carcinoma. Additionally, MSK experts shared their perspectives on previously reported groundbreaking trials of new treatment approaches in colorectal cancer and HER2-low metastatic breast cancer.

Memorial Sloan Kettering Cancer Center’s urology service is comprised of a multidisciplinary team of experts that is among the most experienced in the field. Patients referred to MSK will have access to life-saving clinical trials, pioneering research, and the latest therapies and surgical advances that are tailored specifically for them. Hear from MSK surgeon Bernard Bochner as he talks about achieving the best coordinated care possible for patients.

The MSK Clinical Research Roundup keeps physicians up to date on the latest and most noteworthy patient treatments, clinical trials, and translational research happening at MSK.

Tumor genomics and clinicopathologic features better predict recurrent lung adenocarcinoma (LUAD) following primary resection compared with the TNM classification system, according to a recent study from MSK.

Signet ring cell cancer (SRCC) was detected in the vast majority of patients with CDH1 mutations following total gastrectomy.

A large cohort of patients with high-risk bladder cancer who underwent radical cystectomy and urinary tract reconstruction at Memorial Sloan Kettering Cancer Center reported favorable recovery and health-related quality of life within 24 months across most outcome measures.

Sequencing circulating tumor cell-free DNA (cfDNA) in cerebrospinal fluid (CSF) improved diagnosis, decision-making, and clinical care in pediatric and adolescent and young adult (AYA) patients with brain tumors.

Memorial Sloan Kettering Cancer Center (MSK) experts presented breakthrough findings in several areas of cancer research at the 2022 Annual ASCO meeting, focusing on rectal, breast, leptomeningeal metastasis, pancreatic, and lung cancers.

Rectal cancer patients saw their tumors disappear in a clinical trial involving immunotherapy at Memorial Sloan Kettering Cancer Center—without surgery, radiation, or chemotherapy.